Market Place
Sourcing Support
Kite to Present CAR T-Cell Therapy Data at ASH 2024
05 Nov 2024 //
BUSINESSWIRE
Gilead`s Kite Exits China Joint Venture With Fosun
19 Sep 2024 //
FIERCE PHARMA
Kite Pharma to Evaluate Cellares’ Automated Manufacturing Platform
28 Jun 2024 //
CONTRACT PHARMA
Gilead`s Kite signs on with Cellares for cell therapy manufacturing test
27 Jun 2024 //
FIERCE PHARMA
Gilead And Kite Pharma Celebrate Pride Month
19 Jun 2024 //
ACCESSWIRE
Ex-Kite leader helms Santa Ana’s ship with $168M in hand
13 Jun 2024 //
FIERCE BIOTECH
Kite`s Tecartus Shows Sustained OS In Relapsed/Refractory ALL
03 Jun 2024 //
BUSINESSWIRE
Kite`s Yescarta Shows Promise In Relapsed/Refractory CNS Lymphoma
03 Jun 2024 //
BUSINESSWIRE
Cytiva rolls out new CAR-T manufacturing platform developed with Gilead’s Kite
30 May 2024 //
FIERCE PHARMA
Kite EHA 2024 Data Show CAR T-Cell Therapy Advances
14 May 2024 //
BUSINESSWIRE
Kite & Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma
11 May 2024 //
PHARMABIZ
Arcellx & Kite Continue Momentum with Advances in Multiple Myeloma Program
09 May 2024 //
BUSINESSWIRE
Gilead, Kite Highlighting Oncology Portfolio At ASCO 2024
07 May 2024 //
BUSINESSWIRE
Shaw Appointed to Cellares Advisory Board to Advance Cell Therapy Manufacturing
26 Mar 2024 //
BUSINESSWIRE
Kite Gilead’s Kite shortens Yescarta manufacturing time with FDA nod
31 Jan 2024 //
FIERCE PHARMA
U.S. FDA Approves Label Update for Kite’s Yescarta® CAR T-Cell Therapy
21 Dec 2023 //
BUSINESSWIRE
Long-Term Data for Kite’s Yescarta® CAR T-Cell Therapy Presented at ASH 2023
11 Dec 2023 //
BUSINESSWIRE
Analyses Presented at ASH Support Kite’s Tecartus in Patients With Blood Cancers
11 Dec 2023 //
BUSINESSWIRE
Analyses of Kite’s Yescarta®CAR T-Cell Therapy Support Curative Potential in Patients With Non-Hodgkin Lymphomas
11 Dec 2023 //
BUSINESSWIRE
Arcellx, Kite aim to keep chipping away at Carvykti advantage
09 Dec 2023 //
ENDPTS
Gilead cuts 7% of staff at Kite Pharma unit, refreshes strategy
29 Nov 2023 //
FIERCE PHARMA
Kite and Epic Bio Announce Collaboration to Develop New Therapies for Cancer
31 Oct 2023 //
BUSINESSWIRE
Kite enlists Epic to apply epigenetic editing in creating next-gen CAR-T cells
31 Oct 2023 //
ENDPTS
Kite’s Car T-cell Therapy Yescarta Showes Durable Remission in ALYCANTE Study
18 Sep 2023 //
PRESS RELEASE
FDA Lifts Partial Hold on Arcellx’s Multiple Myeloma Trial After Patient Death
16 Aug 2023 //
BIOSPACE
Kite Announces Completion of Marketing Authorization Transfer for Yescarta®
22 Jun 2023 //
BUSINESSWIRE
Kite’s Yescarta and Tecartus therapies show promise
12 Jun 2023 //
PHARMATIMES
Kite’s Tecartus CAR T-cell Therapy Demonstrates 78% Complete Response Rate
06 Jun 2023 //
BUSINESSWIRE
Gilead`s Yescarta cuts risk of death by 27.4% in lymphoma study
06 Jun 2023 //
BUSINESSWIRE
Gilead and Kite Oncology Demonstrate Growing Hematology Pipeline at EHA
01 Jun 2023 //
BUSINESSWIRE
Gilead and Kite Oncology to Showcase Advances Across the Pipeline
17 May 2023 //
BUSINESSWIRE
Roche oncology veteran Perettie to fly Gilead`s CAR-T unit Kite
17 May 2023 //
FIERCE PHARMA
KITE TO PRESENT NEW CAR T-CELL THERAPY DATA ACROSS MULTIPLE INDICATIONS
19 Apr 2023 //
PHARMIWEB
Kite`S Yescarta First Car T-Cell Therapy To Receive Health Canada Authorization
24 Mar 2023 //
NEWSWIRE
Kite Completes Acquisition of Tmunity
22 Feb 2023 //
BUSINESSWIRE
Kite CEO Christi Shaw to depart Gilead CAR-T unit
18 Feb 2023 //
ENDPTS
Kite’s Tecartus Demonstrates Overall Survival Benefit in Pivotal ZUMA-3 Trial
09 Feb 2023 //
BUSINESSWIRE
Kite And Arcellx Close Agreement To Co-Develop CART-DdBCMA In Multiple Myeloma
30 Jan 2023 //
PRESS RELEASE
Yescarta® Now Approved in Japan for Relapsed/Refractory Large B-Cell Lymphoma
22 Dec 2022 //
BUSINESSWIRE
Gilead`s Kite swoops in to buy CAR-T focused Tmunity
21 Dec 2022 //
PRESS RELEASE
Kite to Acquire Tmunity to Pursue Next Generation CAR T-Cell Therapy
20 Dec 2022 //
BUSINESSWIRE
Analyses of Tecartus CAR T-Cell Therapy Provide Evidence Supporting Survival
12 Dec 2022 //
BUSINESSWIRE
Three-Year Follow-Up Analysis of Kite’s Yescarta® CAR T-cell Therapy
12 Dec 2022 //
BUSINESSWIRE
Time to CAR T-cell Therapy May Impact Outcomes for Patients
11 Dec 2022 //
BUSINESSWIRE
Body of Evidence Grows From ZUMA-7 Supporting Treatment With Yescarta Therapy
11 Dec 2022 //
BUSINESSWIRE
Gilead buys into multiple myeloma cell therapy with Arcellx deal
10 Dec 2022 //
BIOPHARMADIVE
Kite and Arcellx Announce Strategic Collaboration to develop CART-ddBCMA
09 Dec 2022 //
BUSINESSWIRE
Daiichi is handing back Yescarta rights to Gilead and Kite
09 Dec 2022 //
FIERCEPHARMA
Supreme Court rejects BMS bid to revive $1.2B patent fine
08 Nov 2022 //
FIERCEPHARMA
Gilead and Kite Oncology Demonstrate Transformative Impact of Cell Therapy
03 Nov 2022 //
BUSINESSWIRE
Gilead`s Kite takes Refuge in new blood cancer licensing pact
20 Oct 2022 //
FIERCEBIOTECH
Former Tmunity CEO Oz Azam unveils not-quite-a-psychedelics biotech
18 Oct 2022 //
ENDPTS
Kite’s Yescarta First CAR T-cell Therapy to Receive EMA for B-cell Lymphoma
18 Oct 2022 //
BUSINESSWIRE
Kite gets FDA to sign off on new California-based vector manufacturing facility
04 Oct 2022 //
ENDPTS
Gilead`s Kite wins all-clear for viral vector production
04 Oct 2022 //
FIERCEPHARMA
EC approves Kite’s cell therapy for treating acute lymphoblastic leukaemia
07 Sep 2022 //
PHARMACEUTICAL-TECHNOLOGY
Kite’s Tecartus Granted EMA for the Treatment of Relapsed
06 Sep 2022 //
BUSINESSWIRE
Gilead hits back at Bristol Myers` Supreme Court petition in CAR-T patent feud
26 Aug 2022 //
FIERCEPHARMA
Kite’s CAR T-cell Therapy Tecartus Receives Positive CHMP Opinion in r/r ALL
22 Jul 2022 //
BUSINESSWIRE
